Humanized Liver Mice Model Market

Humanized Liver Mice Model Market Forecast

• Humanized liver mice model market value is expected to reach USD 197.3 Mn in 2033, up from USD 121.3 Mn recorded in 2026.
• Global humanized liver mice model market is projected to witness a CAGR of 7% during the forecast period from 2026 to 2033.

Humanized Liver Mice Model Market Insights

1. Humanized mice models have become a promising substitute for conventional animal models.
2. The human liver acts as a storage place for several significant pathogens, which cause about half a billion infections and result in between 2.5 and 4.5 million fatalities per year.
3. Humanized liver mice models are being used to study the progression of liver diseases and evaluate potential therapeutic interventions
4. Several ongoing investigations are focused on developing innovative liver mouse models that closely resemble human physiology.
5. Originally, liver mouse models were established through the transplantation of either human liver cells or hepatic cancer cells into immunocompromised mice.
6. The outcomes, although, displayed irregularity and lack of dependability. Consequently, researchers created mice with weakened immune systems that naturally destroy their livers.
7. The destruction enables human liver cells to grow and replace the original liver, culminating in developing stable models of mice with humanized livers.
8. The growth of the humanized mouse and rat model market is primarily driven by the increasing utilization of humanized models in drug discovery research.
9. The oncology segment is at the forefront of the expansion of the humanized mouse model industry.
10. The growing demand for personalized medicine, and the rising research and development activities in the pharmaceutical and biotechnology industry are the key drivers for the humanized liver mice model market

A Look Back and a Look Forward - Comparative Analysis

The humanized liver mice model market experienced moderate growth before 2023. The market was driven primarily by increasing research on liver diseases, advancements in genetic engineering, and the rising prevalence of liver disorders such as hepatitis and liver cancer. North America largely dominated the market due to substantial investments in biomedical research and robust healthcare infrastructure.

The market for humanized liver mice model is anticipated to witness accelerated growth post-2024. This surge is expected due to technological advancements leading to the development of more reliable and consistent models.

Enhanced capabilities in genetic modifications and better immunodeficient mouse strains that can naturally replace their liver with human liver cells are significant factors contributing to this growth. Also, the increasing number of FDA approvals for hepatitis and other liver disease drugs largely dependent on these models highlights their essential role in drug development.

Key Growth Determinants

• Technological Advancements

The humanized liver mice model market is experiencing significant growth driven by technological advancements. These advancements have developed more sophisticated and reliable models that mimic human liver physiology better. For instance,

Newer models such as PPARalpha and AFC8-based mice demonstrate improved consistency and stability in liver function. The evolution from simple immunodeficient mice implanted with human liver cells to more advanced models that naturally replace their liver with human cells has dramatically enhanced research outcomes.

Innovations facilitate more accurate studies in drug metabolism, liver disease mechanisms, and therapeutic testing, thereby boosting the market's growth potential. 

• Rising Prevalence of Liver Diseases

Another critical growth driver for the humanized liver mice model market is the global prevalence of liver diseases. Conditions such as hepatitis B and C, liver cirrhosis, and liver cancer have seen a surge, necessitating extensive research and development of new treatments.

Humanized liver mice models play a crucial role in understanding disease mechanisms and testing potential therapies in a preclinical setting. The global burden of liver diseases, particularly in regions with high endemic rates like Asia and Africa, underscores the demand for these models;

Increased need for effective preclinical testing models is propelling market growth as researchers and pharmaceutical companies invest more in developing and utilizing humanized liver mice models. ​

• Increasing FDA Approvals for Hepatitis Drugs

The increasing number of FDA approvals for hepatitis drugs is a significant growth driver for the market for humanized liver mice model. The approval process for new drugs requires extensive preclinical testing to ensure safety and efficacy for which humanized liver mice models are invaluable.

The trend of increasing drug approvals, particularly in the treatment of hepatitis, highlights the critical role of these models in drug development.

There was a noticeable increase in approved hepatitis treatments, reflecting the intensified research and validation efforts using humanized liver mice models during the last decade. This trend not only underscores the importance of these models in pharmaceutical research but also stimulates further investment and innovation in this market segment. ​

Key Growth Barriers

• High Costs of Humanized Liver Mice Models

The high cost of humanized liver mice models presents a significant restraint to market growth. These models, which involve complex genetic modifications and require specialized care, can be prohibitively expensive. For instance,

Immunodeficient mice used for liver studies can cost between $140 and $500 each, while more sophisticated chimeric humanized liver mice models can range from $2,500 to $3,500 per mouse​.

High costs of mice are due to the intricate processes involved in developing and maintaining these models, including the use of advanced technologies and the need for specialized shipping containers to ensure their safe transport.

The said financial burden limits the accessibility of these models, particularly for smaller research institutions and companies with limited budgets, thereby hindering wider adoption and humanized liver mice model market expansion​.

• Stringent Regulatory Requirements

Stringent regulatory requirements are another major restraint affecting the market for humanized liver mice model. The use of animal models in research is subject to rigorous ethical and regulatory scrutiny, aimed at ensuring humane treatment and justifiable scientific use.

Regulatory frameworks like the 3Rs principle (replace, reduce, and refine) are enforced to minimize the use of animals and encourage the adoption of alternative methods wherever possible​. These regulations necessitate extensive documentation and compliance efforts, which can delay research timelines and increase operational costs.

The approval process for using humanized liver mice models in specific studies can be cumbersome and time-consuming, posing significant challenges to researchers and companies. These regulatory hurdles not only slow down the pace of scientific progress but also add to the overall cost and complexity of conducting research, thus restraining the market for humanized liver mice model market growth​

Humanized Liver Mice Model Market Trends and Opportunities

• Integration of Advanced Genetic Editing Techniques

One significant trend in the humanized liver mice model market is the integration of advanced genetic editing techniques like CRISPR-Cas9. The technology allows for precise modifications of the mouse genome to create more accurate and reliable humanized liver models.

CRISPR-Cas9 has facilitated the development of models with specific human gene expressions and liver functions closely mimicking human physiology. This trend is driven by the need for better models to study complex liver diseases and test new drugs more effectively.

The precision and efficiency of CRISPR-Cas9 reduce the time and cost associated with developing humanized models, making them more accessible to a broad range of researchers​. The adoption of advanced genetic editing tools is expected to enhance the utility of humanized liver mice models in preclinical studies.

As the technologies become more refined and widely adopted, the humanized liver mice model market is likely to see sustained growth and innovation​.

• Expansion in Emerging Markets

An exciting opportunity for the humanized liver mice model market lies in the expansion into emerging markets, particularly in regions such as Asia Pacific and Latin America. Governments and private sectors are investing heavily in healthcare infrastructure and research capabilities, providing a robust and secure foundation for the growth of the humanized liver mice model market, ensuring a promising future for our investment.

The high prevalence of hepatitis B and C in these regions underscores the need for effective preclinical models to facilitate the development of new treatments​. Expanding into these emerging markets offers companies a pool of opportunities to enter a new revenue stream and diversify their market presence.

Companies can leverage the growing demand and contribute to advancing liver disease research globally by establishing collaborations with local research institutions and investing in regional facilities.

How Does Regulatory Scenario Shape the Humanized Liver Mice Model Market?

Regulatory agencies like the FDA and EMA are increasingly focused on the safety and efficacy of preclinical models used in drug development. Humanized liver mice, models must meet stringent safety standards, ensuring their reliability and accuracy in mimicking human liver function.

Regulatory bodies emphasize ethical considerations and animal welfare in research, promoting the use of humanized liver mice models as they can reduce the number of animals needed by providing more relevant human-like data.

Governments and regulatory bodies often provide funding and grants for research involving advanced preclinical models, including humanized liver mice. Further, efforts are underway to harmonize regulatory standards globally, ensuring that data from humanized liver mice models are accepted across different jurisdictions.

Fairfield’s Ranking Board

Segments Covered in the Report

• Genetic Humanized Model Dominates the Model Type Segmentation

The importance of the genetically humanized mouse model segment lies in its crucial role in expediting drug discovery and development. Pharmaceutical and biotechnology enterprises, as well as research institutions continue to aggressively use genetic humanized mouse models. These models have established themselves as the primary source of revenue for experimental analysis and medication development in the sector.

• Oncology dominates the application segment of the market.

The oncology segment is at the forefront of the expansion of the humanized mouse model industry. Oncology research mostly depends on humanized mouse models to comprehend the biology of cancer, develop novel treatments, and evaluate the efficacy of drugs.

These models enhance the accuracy and reliability of preclinical research by replicating the complex environment of human tumours. The oncology section assumes leadership due to the urgent need for advanced cancer research and the development of therapeutic methods.

The demand for humanized mouse models in this research is expected to be high as long as cancer continues to be a global health issue driving progress and innovation in cancer treatments.

Regional Analysis

• North America to Exhibit Significant Growth

humanized liver mice model market in North America is projected to experience substantial growth. The increasing need for personalized treatment is driving the adoption of humanized mouse models in preclinical research for pharmaceutical development.

Advancements in genetic engineering and genome editing techniques have made it easier to develop humanized mouse models that are more accurate and relevant. Pharmaceutical companies and academic institutions in North America are increasingly utilizing these models to study human diseases and assess potential remedies.

The robust healthcare system and substantial financial investments in biomedical research in the region contribute to the hopeful future of North America's rat and mouse model market.

Fairfield’s Competitive Landscape Analysis

The humanized liver mice model market's competitive landscape is characterized by several key players focusing on innovation and expanding their product portfolios. The key companies invest significantly in research and development to create reliable and efficient humanized models.

Strategic partnerships, mergers, and acquisitions are joint as firms aim to enhance their market position and capabilities. Additionally, the competition is driven by advancements in genetic editing technologies like CRISPR-Cas9, enabling more sophisticated models to be developed. The increasing demand for preclinical testing and the rising prevalence of liver diseases further intensify humanized liver mice model market competition.

Key Market Companies

• Ingenious Targeting Laboratory
• Axenis S.A.S
• Trans Genic Inc.
• Horizon Discovery Group PLC
• HuMurine Technologies
• Champions Oncology Inc.
• Genoway S.A.
• Crown Bioscience Inc.
• Taconic Biosciences Inc.
• The Jackson Laboratory
• Vitalstar Biotechnology Co. Ltd.

An Expert’s Eye

• Increasing utilization of humanized liver mice models for accurate human liver function studies creates opportunities in biomedical research.
• The growing prevalence of liver diseases, such as hepatitis, cirrhosis, and liver cancer, caters to the scope of research and development activities.
• Enhanced ability to predict human responses to therapies, improving drug development outcomes.
• The humanized liver mice model market is set for significant expansion with broad applications in biomedical research.

Global Humanized Liver Mice Model Market is Segmented as -

By Model Type

• Genetic
• Cell-based

 By Application

• Oncology
• Immunology
• Neuroscience

By End User

• Research Institutes
• Biotech Companies
• Hospitals

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East & Africa